Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 5,145 matching trials from the live ClinicalTrials.gov search.
Conditions
Cardiac Allograft Vasculopathy, Heart Transplant Recipients
Interventions
Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper), Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 16 more
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Understanding Oral Nicotine Pouch Use in Healthy Volunteers

NCT07829939
Conditions
Healthy Adult Participants
Interventions
0 mg oral nicotine pouches, 3 mg oral nicotine pouches, 6 mg oral nicotine pouches, cigarette or e-cigarette
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
HIV Infections, Cardiovascular Diseases, Hypertension
Interventions
Indinavir sulfate, Ritonavir, Amlodipine, Diltiazem HCl
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
9
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 6 more
Conditions
Meningioma, Meningioma, Malignant, Recurrent Meningioma
Interventions
Hypofractionated Stereotactic Radiosurgery (SRS), Magnetic Resonance Imaging (MRI), Computed Tomography (CT)
Radiation · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Completed No phase listed Observational Accepts healthy volunteers

San Francisco Stop Smoking App - Pilot Study

NCT01626326
Conditions
Recruitment
Interventions
San Francisco Stop Smoking iPhone app
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
9,935 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Conditions
Psoriasis, Atopic Dermatitis
Interventions
In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Study of RhinAer ARC Stylus for Treating Chronic Rhinitis (RELIEF)

NCT04614324
Conditions
Chronic Rhinitis
Interventions
RhinAer ARC Stylus
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
12
States / cities
Goodyear, Arizona • Roseville, California • San Francisco, California + 9 more
Conditions
Mild Cognitive Impairment
Interventions
Tesamorelin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
Los Angeles, California • Palm Springs, California • San Diego, California + 1 more
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Research Center for Clinical Neuroimmunology and Neuroscience Basel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hepatitis C
Interventions
peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 70 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 5 more
Conditions
Intestinal Failure Associated Liver Disease
Interventions
NST-6179 Part A, NST-6179 Part B, Matched Placebo
Drug · Other
Lead sponsor
NorthSea Therapeutics B.V.
Industry
Eligibility
16 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
13
States / cities
Scottsdale, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more
Terminated Phase 1 Interventional Results available

Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus

NCT03239470
Conditions
Pemphigus Foliaceus, Pemphigus Vulgaris
Interventions
Cohort 1: 1.0 x 10^8 PolyTregs, Cohort 2: 2.5x10^8 PolyTregs
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Francisco, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Completed Not applicable Interventional

Depression Management Project

NCT01150604
Conditions
Major Depression, Depression
Interventions
Self-help cognitive-behavioral online course
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neurocysticercosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
San Francisco, California • Bethesda, Maryland • Dallas, Texas + 1 more
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib, Fulvestrant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
134
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more
Active, not recruiting No phase listed Observational

OCS Heart Perfusion Post-Approval Registry

NCT05047068
Conditions
Transplant
Interventions
OCS Heart System
Device
Lead sponsor
TransMedics
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
27
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 20 more
Conditions
Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Interventions
VX-880, VX-017
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • Miami, Florida + 8 more
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study With Pravastatin and Cyclosporine

NCT01497483
Conditions
Healthy
Interventions
Pravastatin alone, Pravastatin and Cyclosporine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Conditions
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
Interventions
Treosulfan, Fludarabine Phosphate, Tacrolimus, Methotrexate, Lapine T-Lymphocyte Immune Globulin, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Quality-of-Life Assessment, Echocardiography, Multigated Acquisition Scan, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, X-Ray Imaging, Computed Tomography
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
1 Year to 49 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
24
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 20 more
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Nivolumab (Cohort A), Ipilimumab (Cohort A, B and C), Hydroxychloroquine (HCQ) (Cohort B), Nab-paclitaxel (nP) (Cohort A, B and C), Gemcitabine (gem) (Cohort A, B and C), NG350A (Cohort C)
Drug
Lead sponsor
Cancer Insight, LLC
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 3 more
Conditions
COVID-19
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more
Conditions
Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor, Rhabdomyosarcoma, Neuroblastoma, Medulloblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Palbociclib, Temozolomide, Irinotecan, Topotecan, Cyclophosphamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 20 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Conditions
Heart Failure
Interventions
Daily Voice Recording
Other
Lead sponsor
Noah Labs
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Chronic Pelvic Pain Syndrome (CPPS), Chronic Pelvic Pain Syndrome, Chronic Pelvic Pain
Interventions
Pelvic floor yoga, Physical conditioning
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California